Azithromycin does not reduce recurrent coronary events - 24/08/11
Abstract |
Question |
Does azithromycin reduce the incidence of coronary events in people with a previous myocardial infarction?
Study design |
Double-blind randomised placebo-controlled trial.
Main results |
There was no difference in the number of combined primary events in people treated with azithromycin compared to placebo (RR 7%, 95% CI −5% to +17%), or any individual type of event (p⩾0.31). This result did not change after adjusting the analysis for cardiac risk factors. Gastrointestinal tract-related adverse events were more common with azithromycin compared with placebo (e.g. diarrhoea 8.1% vs. 1.4%, statistical significance not reported). Respiratory tract adverse events were less common in the azithromycin group (6.4% vs. 9.4%, p<0.001).
Authors’ conclusions |
Treatment with azithromycin in stable patients with a history of myocardial infarction does not reduce the rate of coronary heart disease events.
Le texte complet de cet article est disponible en PDF.Keywords : Myocardial infarction, Coronary disease, Antibiotics, Azithromycin, Randomised controlled trial
Plan
Abstracted from: O’Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459–1466. |
Vol 8 - N° 2
P. 105-106 - avril 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?